Current Problems in Cancer
Volume 33, Issue 3 , Pages 203-218 , May 2009

Health-Related Quality of Life and Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy

  • Richard McQuellon, PhD

      Affiliations

    • Professor, Department of Medicine, Section of Hematology and Oncology, Director of Psychosocial Oncology and Cancer Patient Support Program, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina
    • ,
  • Katie E. Duckworth, MA

      Affiliations

    • Doctoral Student/Member, Psychosocial Oncology and Cancer Support Program Team, Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina

References 

  1. Sugarbaker PH, Barofsky I, Rosenberg SA, Gianola FJ. Quality of life assessment of patients in extremity sarcoma clinical trials. Surgery. 1982;91:17–23
  2. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178–3186
  3. McQuellon R, Gavazzi C, Piso P, Swain D, Levine E. Quality of life and nutritional assessment in peritoneal surface malignancy (PSM): Recommendations for care. J Surg Oncol. 2008;98:300–305
  4. McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol. 2001;27:65–73
  5. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570–579
  6. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–376
  7. Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. Qual Life Res. 1995;4:523–531
  8. Grant M, Ferrell B, Schmidt GM, Fonbuena P, Niland JC, Forman SJ. Measurement of quality of life in bone marrow transplantation survivors. Qual Life Res. 1992;1:375–384
  9. Cella DF, Tulsky DS. Measuring quality of life today: Methodological aspects. Oncology. 1990;4:29–38
  10. Cella DF, Tulsky DS. Quality of life in cancer: Definition, purpose, and method of measurement. Cancer Invest. 1993;11:327–336
  11. Cella DF. Methods and problems in measuring quality of life. Support Care Cancer. 1995;3:11–22
  12. Cella DF. Quality of life outcomes: Measurement and validation. Oncology. 1996;10(suppl):233–246
  13. Cella DF, Bonomi AE. Measuring quality of life: 1995 Update. Oncology. 1995;9(suppl):47–60
  14. McQuellon RP, Thaler HT, Cella D, Moore DH. Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: A Gynecologic Oncology Group study. Gynecol Oncol. 2006;101:296–304
  15. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. J Clin Oncol. 2004;22:3113–3119
  16. Verwaal VJ, van Ruth S, de Bree E, van Slooten GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative Surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21:3737–3743
  17. Loggie BW, Fleming RA, McQuellon RP, Russell GB, Geisinger KR. Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg. 2000;66:561–568
  18. McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, et al. Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2003;10:155–162
  19. McQuellon RP, Danhauer SC, Russell GB, Shen P, Fenstermaker J, Stewart JH, et al. Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol. 2007;14:1105–1113
  20. McQuellon RP, Russell GB, Shen P, Stewart JH, Saunders W, Levine EA. Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol. 2008;15:125–133
  21. McQuellon R, Russell G, Campbell C, Duckworth K, Beard R, Shen P, et al. Assessing depressive symptoms with the Center for Epidemiologic Studies Depression-Scale prior to cytoreductive surgery + intraperitoneal hyperthermic chemotherapy. Psycho-Oncology. 2009;18(S1-S96):S42
  22. Alexander R, Mavroukakis S, Libutti S, Pingpank J, Beresneva T, Marden S, et al. Impact of tumor resection (Rxn) and intraperitoneal (IP) chemotherapy (CHRx) on health related quality of life (HRQL) in patients (Pts) with peritoneal surface malignancies (PSM). Ann Surg Oncol. 2004;11:S109
  23. Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P. Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2005;31:53–58
  24. Jess P, Iversen LH, Nielsen MB, Hansen F, Laurberg S, Rasmussen PC. Quality of life after cytoreductive surgery plus early intraperitoneal postoperative chemotherapy for pseudomyxoma peritonei: A prospective study. Dis Colon Rectum. 2008;51:868–874
  25. Tuttle TM, Zhang Y, Greeno E, Knutsen A. Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2006;13:1627–1632
  26. Andrykowski MA, Brady MJ, Greiner CB, Altmaier EM, Burish TG, Antin JH, et al. “Returning to normal” following bone marrow transplantation: Outcomes, expectations and informed consent. Bone Marrow Transplant. 1995;15:573–581
  27. Horning SJ. Follow-up of adult cancer survivors: New paradigms for survivorship care planning. Hematol Oncol Clin North Am. 2008;22:201–210
  28. McQuellon RP, Cowan MA. Turning toward death together: Conversation in mortal time. Am J Hosp Palliat Care. 2000;17:312–318
  29. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: Differences between improvement and worsening. Qual Life Res. 2002;11:207–221
  30. Engel GL. The need for a new medical model: A challenge for biomedicine. Science. 1977;196:129–136
  31. Wilson IB, Cleary PD. Linking clinical variables with health-related quality of life (A conceptual model of patient outcomes). J Am Med Assoc. 1995;273:59–65
  32. Velikova G, Brown JM, Smith AB, Selby PJ. Computer-based quality of life questionnaires may contribute to doctor–patient interactions in oncology. Br J Cancer. 2002;86:51–59
  33. Velikova G, Booth L, Smith AB, Brown PM, Lynch P, Brown JM, et al. Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. J Clin Oncol. 2004;22:714–724
  34. Velikova G, Awad N, Coles-Gale R, Wright EP, Brown JM, Selby PJ. The clinical value of quality of life assessment in oncology practice-a qualitative study of patient and physician views. Psychooncology. 2008;17:690–698

PII: S0147-0272(09)00031-2

doi: 10.1016/j.currproblcancer.2009.06.008

Current Problems in Cancer
Volume 33, Issue 3 , Pages 203-218 , May 2009

Article Tools

* Image Usage & Resolution